Myriad Genetics, Inc. (MYGN) Guidance & Earnings Results
On 2026-07-30 Myriad Genetics, Inc. lowered guidance: "FY2026 guidance revised down due to lower Prenatal Health volumes and more conservative assumptions regarding average revenue per…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MYGNMyriad Genetics, Inc.Follow MYGN — free
—
Price chart with a free account
- Market cap
- 556.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Jul 26 | Lowered | FY2026 guidance revised down due to lower Prenatal Health volumes and more conservative assumptions regarding average revenue per test. · full year |
| 5 May 26 | Reaffirmed | Full-year 2026 guidance reiterated; no specific numbers provided in excerpt. · full year |
| 23 Feb 26 | Reaffirmed | Reiterates 2026 financial guidance; no specific numbers provided · full year |
| 12 Jan 26 | Raised | FY2026 revenue $860-$880M (+6% YoY mid-point), adjusted EBITDA $37-$49M (+43% YoY mid-point) · full year |
| 3 Nov 25 | Reaffirmed | Full-year 2025 guidance reiterated · full year |
| 5 Aug 25 | Raised | FY25 revenue raised to $818M-$828M from $807M-$823M; FY25 adjusted EPS reiterated $(0.02)-$0.02 · full year |
Myriad Genetics, Inc. — questions
- What guidance did Myriad Genetics, Inc. give?
- On 2026-07-30: "FY2026 guidance revised down due to lower Prenatal Health volumes and more conservative assumptions regarding average revenue per test."
- When does Myriad Genetics, Inc. report earnings?
- Myriad Genetics, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Myriad Genetics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.